All Oncology News

The addition of serplulimab to carboplatin and nab-paclitaxel significantly prolonged survival vs chemotherapy alone when used in the first-line treatment of patients with previously untreated locally advanced or metastatic squamous non–small cell lung cancer.

The FDA has granted orphan drug designation to LP-284 for use in the treatment of patients with high-grade B-cell lymphoma harboring MYC and BCL2 rearrangements.

Patients with non–small cell lung cancer harboring acquired EGFR mutations, such as C797S and intrinsic mutations in EGFR represent underserved populations where additional targeted therapies are needed.

The FDA has granted a fast track designation to BI 764532 for use as a therapeutic option in patients with advanced or metastatic DLL3-expressing large-cell neuroendocrine carcinoma of the lung who experienced disease progression after treatment with 1 or more lines of therapy, including platinum-based chemotherapy.

Bradley A. McGregor, MD, expands on the feasibility and safety considerations addressed through the design and methodology of the DAD study; highlights dose-limiting toxicities and early responses seen with sacituzumab govitecan plus enfortumab vedotin in treatment-resistant mUC; and explains how these results support further investigation of other ADC doublets.

Macarena de la Fuente, MD, becomes the first Hispanic elected and will represent neurology on the multidisciplinary board.

Final outcomes from the phase 1b/2 Study 111/KEYNOTE-146 trial, evaluating treatment with lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma, has sparked interest in the use of this combination.

Hope Cottrill, MD, highlights key points that were presented at a State of the Science Summit meeting, including the role of bevacizumab plus PARP inhibitors in ovarian cancer management, how to manage adverse events associated with antibody-drug conjugates, and ongoing research in ovarian cancer risk reduction.

Florida Cancer Specialists & Research Institute, LLC has appointed medical oncologist and hematologist Richard McDonough, MD as Director of Patient Advocacy for the statewide practice.

Neoadjuvant chemotherapy preceding surgery did not result in a significant difference in 5-year overall survival rates compared with concomitant chemoradiotherapy in patients with stage IB2 to IIB cervical carcinoma, according to findings from the phase 3 EORTC-55994 trial.

Florida Cancer Specialists & Research Institute, LLC is now offering an advanced maintenance therapy program that slows the progression of relapsed/refractory multiple myeloma.

Adjuvant treatment with the chemotherapy doublet of pemetrexed and cisplatin did not lead to a significant improvement in overall survival compared with vinorelbine plus cisplatin in patients with stage II to IIIA nonsquamous non–small cell lung cancer.

The FDA has granted an accelerated approval to pirtobrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.

Thomas Powles, MD, MBBS, MRCP, discusses key background information about the EV-302 trial; the efficacy and safety findings from this trial; and the future implications of the data from several emerging trials in urothelial cancer.

Marijo Bilusic, MD, PhD, highlights key points presented at the meeting, including considerations with PARP inhibitor combinations for patients with mCRPC, how disease characteristics factor into treatment selection for patients with hormone-sensitive prostate cancer, and more.

Mrinal M. Gounder, MD, discusses the rationale for investigating nirogacestat in the DeFi trial, highlights patient-reported outcomes with the agent in this study, and discusses potential next steps for better utilizing T2-weighted magnetic resonance imaging in addition to RECIST criteria when assessing tumor volume and dimensions in desmoid tumors.

Innovative new technologies being used exclusively by Florida Cancer Specialists & Research Institute, LLC in Ocala and The Villages are helping to target tumors more precisely, reduce side effects and enhance comfort for patients receiving radiation therapy for the treatment of certain cancers, including breast cancer and head and neck cancers.

Preliminary findings from the phase 3 BOND-003 trial showed that treatment with cretostimogene grenadenorepvec led to sustained and durable complete responses and a tolerable safety profile in patients with high-risk non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin.

The FDA has granted priority review to a supplemental biologics license application for enfortumab vedotin plus pembrolizumab for the frontline treatment of patients with locally advanced or metastatic urothelial cancer.

This commentary examines the use of words and expressions in the oncology domain and the implications of different interpretations by patients and their families from professionals employing this language, including academic authors and members of their clinical teams.

Kathleen N. Moore, MD, MS, discusses the challenges with utilizing immune-targeted therapy for ovarian cancer, expands on the impact of the tumor microenvironment on the effectiveness of immune checkpoint inhibitors, and details ongoing research with different treatment approaches in ovarian cancer.

The triplet combination of sintilimab, chidamide, and bevacizumab resulted in a high 18-week progression-free survival rate with a favorable toxicity profile in patients with microsatellite stable or mismatch repair–proficient metastatic colorectal cancer, according to data from the phase 2 CAPability-01 trial.

Lyudmila A. Bazhenova, MD, expanded on key considerations when navigating the use of perioperative immunotherapy for patients with or without oncogenically-driven lung cancers, the importance of multidisciplinary collaboration when deciding on a treatment plan, and the need for increased and earlier implementation of biomarker testing in all patients with lung cancer.

Pembrolizumab continued to demonstrate at trend toward improved overall survival compared with chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer.

The FDA has granted fast track designation to zotatifin for use in combination with fulvestrant and abemaciclib as second- or third-line therapy for the treatment of patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with disease progression following treatment with endocrine therapy and a CDK4/6 inhibitor.

Dolphins Challenge Cancer and AutoNation are teaming up to address the links between social, economic and environmental factors and breast cancer mortality.

Bradley J. Monk, MD, FACOG, FACS, and Paolo Tarantino, MD, discuss key data with B7-H4–directed antibody-drug conjugates across solid tumor types, the evolving role of antibody-drug conjugates in gynecologic cancers, and the importance of determining optimal sequencing with these agents in breast cancer.

With multiple antibody drug conjugate options now available for patients with HER2-negative metastatic breast cancer, clinicians must consider a variety of factors when selecting and sequencing therapies.

The FDA has granted clearance for an investigational new drug application for a phase 1/2 safety lead-in trial investigating the engineered tumor-infiltrating lymphocyte KSQ-001EX in patients with melanoma, head and neck squamous cell carcinoma, and non–small cell lung cancer.

Nadofaragene firadenovec-vncg led to encouraging rates of high-grade recurrence-free survival and overall survival in patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.